Construction and protective efficacy of a novel Streptococcus pneumoniae fusion protein vaccine NanAT1-TufT1-PlyD4

During the past decades, with the implementation of pneumococcal polysaccharide vaccine (PPV) and pneumococcal conjugate vaccines (PCVs), a dramatic reduction in vaccine type diseases and transmissions has occurred. However, it is necessary to develop a less expensive, serotype-independent pneumococcal vaccine due to the emergence of nonvaccine-type pneumococcal diseases and the limited effect of vaccines on colonization. As next-generation vaccines, conserved proteins, such as neuraminidase A (NanA), elongation factor Tu (Tuf), and pneumolysin (Ply), are promising targets against pneumococcal infections. Here, we designed and constructed a novel fusion protein, NanAT1-TufT1-PlyD4, using the structural and functional domains of full-length NanA, Tuf and Ply proteins with suitable linkers based on bioinformatics analysis and molecular cloning technology. Then, we tested whether the protein protected against focal and lethal pneumococcal infections and examined its potential protective mechanisms. The fusion protein NanAT1-TufT1-PlyD4 consists of 627 amino acids, which exhibits a relatively high level of thermostability, high stability, solubility and a high antigenic index without allergenicity. The purified fusion protein was used to subcutaneously immunize C57BL/6 mice, and NanAT1-TufT1-PlyD4 induced a strong and significant humoral immune response. The anti-NanAT1-TufT1-PlyD4 specific IgG antibody assays increased after the first immunization and reached the highest value at the 35th day. The results from in vitro experiments showed that anti-NanAT1-TufT1-PlyD4 antisera could inhibit the adhesion of Streptococcus pneumoniae (S. pneumoniae) to A549 cells. In addition, immunization with NanAT1-TufT1-PlyD4 significantly reduced S. pneumoniae colonization in the lung and decreased the damage to the lung tissues induced by S. pneumoniae infection. After challenge with a lethal dose of serotype 3 (NC_WCSUH32403), a better protection effect was observed with NanAT1-TufT1-PlyD4-immunized mice than with the separate full-length proteins and the adjuvant control; the survival rate was 50%, which met the standard of the marketed vaccine. Moreover, we showed that the humoral immune response and the Th1, Th2 and Th17-cellular immune pathways are involved in the immune protection of NanAT1-TufT1-PlyD4 to the host. Collectively, our results support that the novel fusion protein NanAT1-TufT1-PlyD4 exhibits extensive immune stimulation and is effective against pneumococcal challenges, and these properties are partially attributed to humoral and cellular-mediated immune responses.

[1]  C. Van Sant,et al.  Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. , 2022, Vaccine.

[2]  Feng Xue,et al.  Extraintestinal pathogenic Escherichia coli utilizes the surface-expressed elongation factor Tu to bind and acquire iron from holo-transferrin , 2022, Virulence.

[3]  B. Gessner,et al.  Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine , 2022, JAMA network open.

[4]  Xuemei Zhang,et al.  IL-4 plays an essential role in DnaJ-ΔA146Ply-mediated immunoprotection against Streptococcus pneumoniae in mice. , 2022, Molecular immunology.

[5]  Alan D. Lopez,et al.  Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis , 2022, The Lancet.

[6]  Two New Pneumococcal Vaccines-Prevnar 20 and Vaxneuvance. , 2021, JAMA.

[7]  K. Yao,et al.  Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines , 2021, Human vaccines & immunotherapeutics.

[8]  Wei Zhou,et al.  Molecular Characterization Based on Whole-Genome Sequencing of Streptococcus pneumoniae in Children Living in Southwest China During 2017-2019 , 2021, Frontiers in Cellular and Infection Microbiology.

[9]  E. Miyaji,et al.  Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies , 2021, Vaccines.

[10]  Çiğdem Yılmaz Çolak.  Computational Design of a Multi-epitope Vaccine Against Clostridium chauvoei: An Immunoinformatics Approach , 2021, International Journal of Peptide Research and Therapeutics.

[11]  K. Tomono,et al.  Mechanisms Underlying Pneumococcal Transmission and Factors Influencing Host-Pneumococcus Interaction: A Review , 2021, Frontiers in Cellular and Infection Microbiology.

[12]  Chaim A. Schramm,et al.  Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. , 2021, Immunity.

[13]  Yan Liu,et al.  Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials , 2021, The Lancet Infectious Diseases.

[14]  Y. Tseng,et al.  Novel Virulence Role of Pneumococcal NanA in Host Inflammation and Cell Death Through the Activation of Inflammasome and the Caspase Pathway , 2021, Frontiers in Cellular and Infection Microbiology.

[15]  N. Srinivasan,et al.  Conformational Strain Indicated by Ramachandran Angles for the Protein Backbone Is Only Weakly Related to the Flexibility. , 2021, The journal of physical chemistry. B.

[16]  An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study , 2021, Scientific reports.

[17]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[18]  J. Ravetch,et al.  The role of IgG Fc receptors in antibody-dependent enhancement , 2020, Nature Reviews Immunology.

[19]  K. Jansen,et al.  Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Verma,et al.  Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis , 2020, Frontiers in Immunology.

[21]  K. Killeen,et al.  Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid , 2020, Vaccine.

[22]  Andries J. van Tonder,et al.  A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus , 2020, mBio.

[23]  D. van Baarle,et al.  Vaccines to Protect Older Adults against Pneumococcal Disease. , 2020, Interdisciplinary topics in gerontology and geriatrics.

[24]  C. Poh,et al.  Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection , 2020, Vaccines.

[25]  B. Brunelli,et al.  Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation. , 2020, Vaccine.

[26]  Feng-hua Liu,et al.  A systematic analysis , 2020 .

[27]  R. Tweten,et al.  Pneumolysin Induces 12-Lipoxygenase–Dependent Neutrophil Migration during Streptococcus pneumoniae Infection , 2019, The Journal of Immunology.

[28]  J. Mascola,et al.  Novel vaccine technologies for the 21st century , 2019, Nature Reviews Immunology.

[29]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[30]  A. Anzueto,et al.  International prevalence and risk factors evaluation for Drug-Resistant Streptococcus pneumoniae pneumonia. , 2019, The Journal of infection.

[31]  N. Kobayashi,et al.  Prevalence of Various Vaccine Candidate Proteins in Clinical Isolates of Streptococcus pneumoniae: Characterization of the Novel Pht Fusion Proteins PhtA/B and PhtA/D , 2019, Pathogens.

[32]  Hong Zhang,et al.  Epidemiology Characteristics of Streptococcus pneumoniae From Children With Pneumonia in Shanghai: A Retrospective Study , 2019, Front. Cell. Infect. Microbiol..

[33]  B. Greenwood,et al.  Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants. , 2019, Vaccine.

[34]  S. Gaffen,et al.  The IL-17 Family of Cytokines in Health and Disease. , 2019, Immunity.

[35]  Jeremy S. Brown,et al.  Mechanisms of Naturally Acquired Immunity to Streptococcus pneumoniae , 2019, Front. Immunol..

[36]  A. Saitoh,et al.  Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection. , 2019, Vaccine.

[37]  J. Weiser,et al.  Streptococcus pneumoniae: transmission, colonization and invasion , 2018, Nature Reviews Microbiology.

[38]  A. Bhattacharjee,et al.  Impact of a non‐synonymous Q281R polymorphism on structure of human Lipoprotein‐Associated Phospholipase A2 (Lp‐PLA2) , 2018, Journal of cellular biochemistry.

[39]  V. Prajapati,et al.  Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein , 2018, Scientific Reports.

[40]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[41]  V. Prajapati,et al.  Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach , 2017, Scientific Reports.

[42]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[43]  C. Quach,et al.  The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. , 2016, Vaccine.

[44]  M. Briel,et al.  The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials. , 2016, Deutsches Arzteblatt international.

[45]  Zhong-yu Hu,et al.  Advances in aluminum hydroxide-based adjuvant research and its mechanism , 2015, Human vaccines & immunotherapeutics.

[46]  P. Zipfel,et al.  Tuf of Streptococcus pneumoniae is a surface displayed human complement regulator binding protein. , 2014, Molecular immunology.

[47]  Irini A. Doytchinova,et al.  AllergenFP: allergenicity prediction by descriptor fingerprints , 2014, Bioinform..

[48]  Hong Wang,et al.  Mucosal Immunization with Recombinant Fusion Protein DnaJ-ΔA146Ply Enhances Cross-Protective Immunity against Streptococcus pneumoniae Infection in Mice via Interleukin 17A , 2014, Infection and Immunity.

[49]  Abdelmonaem Messaoudi,et al.  Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β-lactamase , 2013, Theoretical Biology and Medical Modelling.

[50]  J. Parkhill,et al.  Pneumococcal Capsular Switching: A Historical Perspective , 2012, The Journal of infectious diseases.

[51]  Yibing Yin,et al.  Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae. , 2011, Vaccine.

[52]  Todd M. Gierahn,et al.  T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. , 2011, Cell host & microbe.

[53]  S. Opal,et al.  Pathogenesis, treatment, and prevention of pneumococcal pneumonia , 2009, The Lancet.

[54]  T. Cherian,et al.  Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates , 2009, The Lancet.

[55]  Wei Li,et al.  ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.

[56]  Manfred J. Sippl,et al.  Thirty years of environmental health research--and growing. , 1996, Nucleic Acids Res..

[57]  Irini A. Doytchinova,et al.  BMC Bioinformatics BioMed Central Methodology article VaxiJen: a server for prediction of protective antigens, tumour , 2007 .

[58]  W. Schaffner,et al.  Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. , 2006, The New England journal of medicine.

[59]  S. Schrag,et al.  Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. , 2004, JAMA.

[60]  E. Tuomanen,et al.  Role of Novel Choline Binding Proteins in Virulence of Streptococcus pneumoniae , 2000, Infection and Immunity.

[61]  Jeremy Fairbank,et al.  Historical Perspective , 1987, Do We Really Understand Quantum Mechanics?.

[62]  R D Appel,et al.  Protein identification and analysis tools in the ExPASy server. , 1999, Methods in molecular biology.

[63]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[64]  Robert C. Wolpert,et al.  A Review of the , 1985 .